about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Striv­ing for high­er res imag­ing of cells, Har­vard team de­buts start­up with back­ing from ARCH, North­pond

6 years ago
Financing
Startups

Don't get too ex­cit­ed about Eli Lil­ly's up­com­ing Alzheimer's read­out just yet, R&D chief cau­tions

6 years ago
R&D

Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

6 years ago
Financing

Vas Narasimhan wants No­var­tis to have a big fo­cus on Chi­na. Here’s what that looks like

6 years ago
China
Pharma

Sanofi pol­ish­es rare dis­ease pro­file as Nie­mann-Pick drug scores promis­ing PhII/III da­ta — there's just one ...

6 years ago
R&D

No­var­tis re­thinks CML strat­e­gy for next-gen al­losteric drug due for a piv­otal read­out lat­er this year

6 years ago
R&D

How do Amer­i­can sci­en­tists get em­broiled in Chi­na scan­dals? Mof­fitt in­ves­ti­ga­tion sheds some light

6 years ago
People
China

Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

6 years ago
People
Cell/Gene Tx

In­cyte scores much need­ed PhI­II suc­cess — and of course it’s de­liv­ered by rux­oli­tinib

6 years ago
R&D

Mike Bloomberg joins a grow­ing cho­rus of De­mo­c­ra­t­ic pres­i­den­tial can­di­dates threat­en­ing to go af­ter drug patents

6 years ago
People
Pharma

Mer­ck KGaA match­es lofty R&D goals with €250M in­vest­ment in­to a new clin­i­cal man­u­fac­tur­ing site in Switzer­land

6 years ago
R&D

Af­ter a brief break, As­traZeneca is back at di­vest­ing — hand­ing off hy­per­ten­sion meds for $350M

6 years ago
Deals

Ab­b­Vie do­nates $1M+ of the HIV drug that Chi­na is now rec­om­mend­ing for coro­n­avirus treat­ment

6 years ago
China
Coronavirus

Deer­field vaults to the top of cell and gene ther­a­py CD­MO game with $1.1B fa­cil­i­ty at Philadel­phi­a's newest bio­phar­ma ...

6 years ago
Outsourcing
Cell/Gene Tx

FDA waves Epizyme's $186K rare can­cer drug through to mar­ket — now get ready for the sec­ond act

6 years ago
Pharma
FDA+

PureTech bags $200M from sale of Karuna shares — still siz­zling from promis­ing schiz­o­phre­nia da­ta

6 years ago
Deals

Roche cracks Chi­na's ADC mar­ket open as Kad­cy­la scores its first breast can­cer OK in the coun­try

6 years ago
China
Pharma

Brex­it fears, Wood­ford woes over­shad­owed UK biotech and cut 2019 fi­nanc­ing by al­most half

6 years ago
Financing

Chica­go in­vestor de­vis­es £250M deal as re­al es­tate grows with UK's biotech sec­tor

6 years ago
Deals

Eli Lil­ly re­serves $470M for new man­u­fac­tur­ing plant — and North Car­oli­na is more than pleased

6 years ago
Pharma

Ko­re­a's Cell­tri­on blue­prints $514M bi­o­log­ics plant in Chi­na, beef­ing up biosim­i­lar, con­tract man­u­fac­tur­ing

6 years ago
Outsourcing

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

6 years ago
People

Chi­na’s fourth rich­est man takes a back seat at the top drug­mak­er he built

6 years ago
People
China

In ac­tive shop­ping mode, Eli Lil­ly plots one deal per quar­ter as it scouts 'Der­mi­ra-like' as­sets up to $5B

6 years ago
Deals
First page Previous page 82838485868788 Next page Last page
A service from the Financial Times